BioCentury
ARTICLE | Clinical News

ARQ 092: Interim Phase I data

April 29, 2013 7:00 AM UTC

Interim data from 20 evaluable patients with advanced or metastatic solid tumors in an open-label, dose-escalation, U.S. Phase I trial showed that oral ARQ 092 led to 7 cases of stable disease for >4 ...